COVID-19 may solidify Australian biotech Mesoblast Limited’s position at the forefront of the development of stem cell therapies as FDA-regulated biologic products, giving a potential second use for the company’s lead allogeneic mesenchymal stem cell (MSC) therapy, Ryoncil (remestemcel-L).
Ryoncil is already in position to become the first MSC therapy with FDA approval. A BLA is under review with...







